GSK plc (OTC: GLAXF) adds Wave Life Sciences (WVE) shares in insider trade

Rhea-AI Filing Summary

GSK plc, through its wholly owned subsidiary Glaxo Group Limited, reported buying 1,470,000 ordinary shares of Wave Life Sciences Ltd. on 12/11/2025 at a price of $19 per share.

After this transaction, the reporting person beneficially owned 18,245,691 Wave Life Sciences ordinary shares, held indirectly via Glaxo Group Limited. The report reflects GSK plc’s role as a shareholder in Wave Life Sciences rather than a change in GSK plc’s own financial results.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GSK plc

(Last) (First) (Middle)

79 NEW OXFORD STREET

(Street)

LONDON X0 WC1A 1DG

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Wave Life Sciences Ltd. [ WVE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	12/11/2025		P		1,470,000	A	$19	18,245,691	I	By Corporation(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares reported herein are held of record by Glaxo Group Limited, a wholly-owned subsidiary of GSK plc (the "Reporting Person").

	/s/ Victoria Whyte, Authorized Signatory, GSK plc	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did GSK plc (GLAXF) report in this insider filing?

GSK plc reported that its subsidiary Glaxo Group Limited bought 1,470,000 ordinary shares of Wave Life Sciences Ltd. on 12/11/2025 at $19 per share.

Which companys stock did GSK plc (GLAXF) buy, and what is its ticker?

The reported purchase was in Wave Life Sciences Ltd. shares, which trade under the ticker WVE.

How many Wave Life Sciences shares does GSK plc (GLAXF) beneficially own after this trade?

Following the reported transaction, the reporting person beneficially owned 18,245,691 ordinary shares of Wave Life Sciences Ltd.

How is GSK plcs (GLAXF) ownership in Wave Life Sciences structured?

The Wave Life Sciences shares are held of record by Glaxo Group Limited, which is described as a wholly owned subsidiary of GSK plc.

Is this insider report for one or multiple reporting persons related to GLAXF?

The document indicates that it is a Form filed by one reporting person rather than by a group.

What is GSK plcs relationship to Wave Life Sciences in this report?

The report identifies the reporting person as a director of Wave Life Sciences Ltd., in addition to being a shareholder through its subsidiary.